Overview
Alomone Labs is pleased to offer the Somatostatin Receptor Antibody Explorer Kit (#AK-104). This Explorer Kit includes antibodies targeting somatostatin receptors along with their respective peptide control antigen. An ideal tool for screening purposes.
Compounds
Product Name | Cat # | Size |
---|---|---|
Anti-Somatostatin Receptor Type 1 (extracellular) Antibody |
ASR-001 | 1 x 50 µl |
Somatostatin Receptor Type 1 (extracellular) Blocking Peptide |
BLP-SR001 | 1 x 40 µg |
Anti-Somatostatin Receptor Type 2 Antibody |
ASR-002 | 1 x 50 µl |
Somatostatin Receptor Type 2 Blocking Peptide |
BLP-SR002 | 1 x 40 µg |
Anti-Somatostatin Receptor Type 2 (extracellular) Antibody |
ASR-006 | 1 x 50 µl |
Somatostatin Receptor Type 2 (extracellular) Blocking Peptide |
BLP-SR006 | 1 x 40 µg |
Anti-Somatostatin Receptor Type 3 Antibody |
ASR-003 | 1 x 50 µl |
Somatostatin Receptor Type 3 Blocking Peptide |
BLP-SR003 | 1 x 40 µg |
Anti-Somatostatin Receptor Type 4 (extracellular) Antibody |
ASR-004 | 1 x 50 µl |
Somatostatin Receptor Type 4 (extracellular) Blocking Peptide |
BLP-SR004 | 1 x 40 µg |
Anti-Somatostatin Receptor Type 5 (extracellular) Antibody |
ASR-005 | 1 x 50 µl |
Somatostatin Receptor Type 5 (extracellular) Blocking Peptide |
BLP-SR005 | 1 x 40 µg |
Scientific Background
Somatostatin is a small cyclic peptide that is widely expressed throughout the central nervous system and peripheral tissues.1 In peripheral tissues, somatostatin exerts inhibitory effects on secretion processes, whereas in the brain it acts as a neurotransmitter in both stimulatory and inhibitory manner.1, 2
Somatostatin mediates its action via six high affinity G-protein coupled receptors (SSTR1, SSTR2a, SSTR2b, SSTR3, SSTR4 and SSTR5) which are encoded by five genes.1,2 Expression of the different receptors is developmentally regulated in a time and tissue-specific manner.2 Somatostatin receptors have been found on a variety of neuroendocrine tumors, such as paragangliomas, carcinoids and breast tumors.3 Synthetic peptide derivatives of somatostatin have been successfully used in the treatment of neuroendocrine malignancies and in in vivo imaging of tumors that are positive to somatostatin receptors.4
- Hofland, L.J. and Lamberts, S.W. (2001) Ann. Oncol. 12, S31.
- Fombonne, J. et al. (2003) Rep. Biol. Endocrinol. 1, 19.
- Slooter, G.D. et al. (2001) Br. J. Surg. 88, 31.
- Schulz, S. et al. (2002) Gyn. Oncol. 84, 235.